Business
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025 Strengthened key leadership with cell therapy and autoimmune expertise across organization Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026 SAN DIE
About this update from Artiva Biotherapeutics, Inc.
[{"type":"image","alt":"Artiva Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Artiva Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":163,"url":"https://media.zenfs.com/en/globenewswire.com/e751b0da58af1d359d964a2a78d6ca43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qlnfoD..J1RiP0FeWYqi_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e751b0da58af1d359d964a2a78d6ca43","width":300,"height":163}},"lazy":false},{"type":"text","content":"Initial data for AlloNK® from autoimmune program expected H1 2025","length":65,"tagName":"p"},{"type":"text","content":"Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025","length":167,"tagName":"p"},{"type":"text","content":"Strengthened key leadership with cell therapy and autoimmune expertise across organization","length":90,"tagName":"p"},{"type":"text","content":"Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026","length":167,"tagName":"p"},{"type":"text","content":"SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31, 2024, and highlighted recent progress.","length":386,"tagName":"p"},{"type":"text","content":"“2024 was a transformational year for Artiva including initiating dosing of AlloNK® in patients with autoimmune disease across our trials, a successful initial public offering strengthening our balance sheet, and expanding key leadership across the organization with expertise in cell therapy and autoimmune disease,” said Fred Aslan, M.D., CEO of Artiva. “We look forward to sharing initial data from our AlloNK® program in autoimmune disease this year. We also look forward to sharing updated clinical data from our non-Hodgkin’s lymphoma (NHL) trial with AlloNK® which continues to mature as one of the strongest data sets for the allogeneic field, de...